Colorectal Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Colorectal Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month19 studies across 16 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| EXEL | Exelixis | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsNCT03845166Dose-Escalation Stage: MTD/recommended dose for XL092 | Phase 1 | Active, not recruiting | 2026-08-31 | in 11 d | 2024-11-19 |
October 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.NCT06447662Part 1 & 2: Incidence of Adverse Events (AEs) | Phase 1 | Active, not recruiting | 2026-10-09 | in 50 d | 2026-07-22 |
| IDYA | IDEAYA Biosciences | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-07-13 |
November 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BNTX | BioNTech SE | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal CancerNCT04486378Disease-free survival (DFS) | Phase 2 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-07-15 |
| CRDF | Cardiff Oncology | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationNCT06106308Objective Response Rate (ORR) | Phase 2 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-06-16 |
| MGNX | MacroGenics | A Study of MGC028 in Participants With Advanced Solid TumorsNCT06723236Number and Types of Adverse Events (AEs) in Participants Receiving MGC028 | Phase 1 | Recruiting | Nov 2026 | ≤ 102 d | 2026-04-27 |
December 2026 9
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and BevacizumabNCT06107413Percentage of Participants with Objective Response | Phase 2 | Active, not recruiting | Dec 2026 | ≤ 133 d | 2025-12-12 |
| AZN | AstraZeneca | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursNCT06147037Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068 | Phase 1 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-07-07 |
| BCAX | Bicara Therapeutics | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsNCT04429542Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs | Phase 1 | Recruiting | 2026-12-31 | in 133 d | 2025-08-15 |
| CNTX | Context Therapeutics Inc. | CT-95 in Advanced Cancers Associated With Mesothelin ExpressionNCT06756035Determine the MTD or RD of CT-95 [Safety and Tolerability] | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-06-12 |
| DCTH | Delcath Systems Inc. | Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant DiseaseNCT06607458hPFS | Phase 2 | Recruiting | Dec 2026 | ≤ 133 d | 2026-06-01 |
| JAZZ | Jazz Pharmaceuticals | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | 2026-12-31 | in 133 d | 2026-07-10 |
| MNPR | Monopar Therapeutics | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-05-21 |
| PFE | Pfizer | Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)NCT05382364Percentage of participants with ≥1 adverse event (AE) | Phase 1 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-03-12 |
| RVMD | Revolution Medicines, Inc. | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsNCT06040541Adverse events | Phase 1 | Recruiting | 2026-12-31 | in 133 d | 2026-06-03 |
January 2027 4
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| IDYA | IDEAYA Biosciences | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsNCT03947385Dose-limiting Toxicity (DLT) | Phase 1/2 | Recruiting | 2027-01-29 | in 162 d | 2026-06-08 |
| ELVN | Enliven Therapeutics | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast CancerNCT06328738Incidence of dose limiting toxicities (DLTs; Phase 1a only) | Phase 1 | Active, not recruiting | Jan 2027 | ≤ 164 d | 2025-11-19 |
| EXEL | Exelixis | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | 2027-01-31 | in 164 d | 2026-08-05 |
| KURA | Kura Oncology, Inc. | KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410Rate of dose-limiting toxicities (DLTs) | Phase 1 | Recruiting | Jan 2027 | ≤ 164 d | 2026-06-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Colorectal Cancer
most recently updated first425 studies match. Showing the first 100 of 425 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesNCT04644068The number of subjects with adverse events/serious adverse events | Phase 1/2 | Active, not recruiting | Drug: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant | Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5 | 702 | 2020-11-12 | 2027-05-28 | in 281 d | 2026-08-19 |
| AZN | AstraZeneca | — | A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerNCT06792695Progression Free Survival (PFS) | Phase 2 | Recruiting | Drug: Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab | Metastatic Colorectal Cancer | 80 | 2025-03-12 | 2027-06-30 | in 314 d | 2026-08-18 |
| CNTX | Context Therapeutics Inc. | $49M | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial CancersNCT07545122Phase 1a: Incidence of Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: CT-202 | Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Urothelial Cancer | 162 | Sep 2026 | Jan 2030 | ≤ 1,260 d | 2026-08-18 |
| EXEL | Exelixis | $13.2B | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 3 | Enrolling by invitation | Drug: Cabozantinib, Zanzalintinib, Atezolizumab, Nivolumab, Abiraterone, Prednisone, Enzalutamide | Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer | 5,000 | 2026-07-30 | 2030-05-31 | in 1,380 d | 2026-08-18 |
| INCY | Incyte Corporation | $24.7B | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibNCT02955940Frequency and types of adverse events and serious adverse events | Phase 2 | Active, not recruiting | Drug: Ruxolitinib, Capecitabine, Regorafenib | Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer | 10 | 2016-11-30 | 2027-09-30 | in 406 d | 2026-08-17 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709Incidence of adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms | 1,109 | 2021-05-27 | 2031-08-31 | in 1,837 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal CancerNCT07222800Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) | Phase 3 | Recruiting | Drug: PF-08634404, Chemotherapy · Biological: Bevacizumab | Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms | 800 | 2025-12-11 | 2030-03-29 | in 1,317 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | Tucatinib Continuation StudyNCT07768358To monitor the safety and tolerability of tucatinib | Phase 4 | Not yet recruiting | Drug: tucatinib | HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer | 175 | 2026-08-24 | 2032-03-13 | in 2,032 d | 2026-08-17 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerNCT06820463Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1. | Phase 2 | Recruiting | Drug: Telisotuzumab Adizutecan, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Panitumumab | Metastatic Colorectal Cancer | 390 | 2025-04-24 | Mar 2028 | ≤ 589 d | 2026-08-14 |
| AZN | AstraZeneca | — | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211Objective response rate (ORR) | Phase 2 | Recruiting | Drug: Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin | Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer | 454 | 2022-09-06 | 2027-10-01 | in 407 d | 2026-08-13 |
| NXTC | NextCure, Inc. | $30M | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsNCT05572684results2026-08-13Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 | Phase 1/2 | Terminatedsponsor's stated reason: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Drug: NC410, pembrolizumab | Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer | 97 | 2022-10-06 | 2025-04-30actual | — | 2026-08-13 |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsNCT07066657Dose Limiting Toxicity (DLT) - Phase Ia | Phase 1 | Recruiting | Drug: MRG007, MRG007 and Bevacizumab | Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer | 572 | 2025-07-25 | Mar 2028 | ≤ 589 d | 2026-08-13 |
| RADX | Radiopharm Theranostics, Ltd | — | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.NCT07272642To assess the safety and tolerability of a single dose of LNTH-2403 | Phase 1 | Not yet recruiting | Drug: LNTH-2403 | Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC) | 16 | 2026-10-30 | 2027-08-30 | in 375 d | 2026-08-12 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| VSTM | Verastem, Inc. | $673M | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerNCT07659795Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only | Phase 2 | Recruiting | Drug: VS-7375, cetuximab, panitumumab, Cetuximab + mFOLFOX6 | Colorectal Cancer | 150 | 2026-07-28 | Jun 2027 | ≤ 314 d | 2026-08-11 |
| PMVP | PMV Pharmaceuticals, Inc | $66M | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt | Phase 1/2 | Recruiting | Drug: rezatapopt, pembrolizumab | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer | 300 | 2020-10-29 | 2026-08-15 | — | 2026-08-10 |
| GH | Guardant Health, Inc. | $21.5B | Shield Post-Approval Study ProtocolNCT06880055observationalPerformance measures of the Shield test will be assessed for the second testing interval | — | Recruiting | Diagnostic test: Shield Blood Test for colo-rectal cancer Screening | Colo-rectal Cancer | 3,375 | 2025-07-14 | 2030-09-01 | in 1,473 d | 2026-08-07 |
| 051910.KS | LG Chem | $13.7B | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C MutationNCT07752875Phase 1: Number of participants with dose-limiting toxicities (DLTs) | Phase 1/2 | Not yet recruiting | Drug: LG00313112 | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Pancreatic Cancer, Locally Advanced Unresectable or Metastatic Solid Tumor | 250 | 2026-12-01 | 2032-10-31 | in 2,264 d | 2026-08-07 |
| AZN | AstraZeneca | — | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationNCT05877599Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours | Phase 1 | Recruiting | Biological: NT-175 | Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS) | 45 | 2023-07-12 | 2029-07-31 | in 1,076 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4257496 in Participants With Cancer (OMNIRAY)NCT07114601Phase 1a Dose Escalation: Maximum Tolerated Dose of LY4257496 | Phase 1 | Recruiting | Drug: LY4257496, Standard of Care Anticancer Therapies · Diagnostic test: LY4257529 | Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms | 421 | 2025-08-06 | Apr 2030 | ≤ 1,349 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4337713 in Participants With FAP-Positive Solid TumorsNCT07213791Phase 1a: Percentage of Participants with Dose Limited Toxicity (DLT) Toxicities | Phase 1 | Recruiting | Drug: LY4337713 | Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma | 241 | 2025-10-22 | Jul 2028 | ≤ 711 d | 2026-08-06 |
| STRO | Sutro Biopharma, Inc. | $365M | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168Part 1A: Number of participants with Dose-limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: STRO-004, Pembrolizumab | Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer | 200 | 2025-11-07 | Dec 2027 | ≤ 498 d | 2026-08-06 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerNCT07284849Progression-Free Survival (PFS) | Phase 3 | Recruiting | Drug: INCA33890, Placebo, Bevacizumab, FOLFOX | CRC (Colorectal Cancer) | 700 | 2026-03-05 | 2028-12-29 | in 862 d | 2026-08-06 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | A Study of IOV-5001 in Adults With Advanced Solid TumorsNCT07743723Phase 1: Safety Assessment | Phase 1/2 | Not yet recruiting | Biological: IOV-5001 | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumors, Unresectable Solid Tumor | 106 | Aug 2026 | Mar 2034 | ≤ 2,780 d | 2026-08-06 |
| EXEL | Exelixis | $13.2B | Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseNCT07750158Disease-Free Survival (DFS) in Zanzalintinib + MK-3475A Versus Placebo as Assessed by the Investigator | Phase 3 | Not yet recruiting | Drug: Zanzalintinib, Placebo · Biological: MK-34574 | Colorectal Cancer | 600 | 2026-08-06 | 2030-04-05 | in 1,324 d | 2026-08-06 |
| EXEL | Exelixis | $13.2B | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | Drug: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab, Nivolumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail | Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI) | 1,394 | 2021-12-14 | 2027-01-31 | in 164 d | 2026-08-05 |
| NTRA | Natera, Inc. | $44.9B | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.NCT07689812To demonstrate that ctDNA-guided intermittent ICI therapy results in at least 50% of patients who do not reinitiate systemic therapy prior to 6 months from randomization. | Not applicable | Not yet recruiting | Device: Signatera Genome ultra-sensitive ctDNA blood test | NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC, Melanoma (Skin Cancer), Melanoma (Skin) Stage IV, CRC, MSI High Colorectal Cancer, DMMR Colorectal Cancer, RCC, Renal Cell Cancer, RCC, Solid Tumors, Metastatic Solid Tumors, Advanced Solid Tumors, Advanced Solid Tumors Cancer | 920 | Dec 2026 | Dec 2033 | ≤ 2,690 d | 2026-08-04 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsNCT06128551Number of patients with adverse events (AEs) in Phase 1b | Phase 1/2 | Recruiting | Drug: Elironrasib, Daraxonrasib | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | 534 | 2023-11-14 | Dec 2028 | ≤ 864 d | 2026-08-03 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsNCT07397338Number of patients with adverse events (AEs) | Phase 1/2 | Recruiting | Drug: Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only), cetuximab (Cohort C2 Only), Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only), Daraxonrasib (Cohort B1 only) | Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC | 370 | 2026-01-30 | May 2029 | ≤ 1,015 d | 2026-08-03 |
| PFE | Pfizer | $155.3B | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal CancerNCT05217446Progression-free Survival (PFS) | Phase 2 | Active, not recruiting | Drug: Encorafenib · Biological: Cetuximab, Pembrolizumab | Metastatic Colorectal Cancer | 108 | 2022-07-11 | 2026-06-19actual | — | 2026-07-31 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.NCT05355701Number of participants with dose limiting toxicities (DLTs) (Part 1 and Part 2) | Phase 1 | Recruiting | Drug: PF-07799933, binimetinib, midazolam, fluorouracil, leucovorin, oxaliplatin · Biological: cetuximab | Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1) | 267 | 2022-07-05 | 2028-04-23 | in 612 d | 2026-07-31 |
| AMGN | Amgen | $229.9B | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationNCT06252649PFS per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) | Phase 3 | Recruiting | Drug: FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb | Metastatic Colorectal Cancer | 450 | 2024-07-17 | 2028-09-25 | in 767 d | 2026-07-30 |
| IPN.PA | Ipsen | $15.5B | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid TumoursNCT06305247Phase 1: Percentage of participants with dose limiting toxicity (DLT) | Phase 1/2 | Active, not recruiting | Drug: IPN01194, IPN01194 | Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor | 36 | 2024-04-03 | 2028-03-20 | in 578 d | 2026-07-30 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsNCT06445062Adverse events | Phase 1/2 | Recruiting | Drug: RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805 | Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | 1,130 | 2024-05-24 | 2027-05-15 | in 268 d | 2026-07-29 |
| ABBV | AbbVie | $457.5B | A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal CancerNCT07525206Phase 3: Objective Response (OR) as assessed by Blinded Independent Central Review (BICR) | Phase 3 | Recruiting | Drug: Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil | Colorectal Cancer | 700 | 2026-05-22 | May 2029 | ≤ 1,015 d | 2026-07-29 |
| CMPX | Compass Therapeutics | $430M | A Study of CTX-009 in Adult Patients With Metastatic Colorectal CancerNCT05513742results2026-07-28Overall Response Rate | Phase 2 | Completed | Drug: CTX-009 | Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer | 49 | 2022-12-08 | 2025-05-15actual | — | 2026-07-28 |
| AZN | AstraZeneca | — | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsNCT06218914Part A (Dose Escalation): Evaluate the safety of KRAS TCRTs in subjects with unresectable, advanced, and/or metastatic solid tumors | Phase 1 | Recruiting | Biological: NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D | Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D | 108 | 2024-03-22 | 2027-08-30 | in 375 d | 2026-07-28 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsNCT03485209Confirmed Objective Response Rate (ORR) (Parts A, B, C, D, E, F, and G) | Phase 2 | Active, not recruiting | Drug: tisotumab vedotin, pembrolizumab, carboplatin, cisplatin | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck | 350 | 2018-06-25 | 2026-03-20actual | — | 2026-07-22 |
| AMGN | Amgen | $229.9B | Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C MutationNCT05198934results2026-07-22Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR | Phase 3 | Completed | Drug: Sotorasib, Panitumumab, Trifluridine and Tipiracil, Regorafenib | Colorectal Cancer (CRC) | 160 | 2022-04-19 | 2025-07-16actual | — | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerNCT05253651Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR) | Phase 3 | Recruiting | Drug: tucatinib, trastuzumab, bevacizumab, cetuximab, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Colorectal Neoplasms | 400 | 2022-10-24 | 2027-12-31 | in 498 d | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsNCT06131840Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV) | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma | 914 | 2023-11-20 | 2029-09-12 | in 1,119 d | 2026-07-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.NCT06447662Part 1 & 2: Incidence of Adverse Events (AEs) | Phase 1 | Active, not recruiting | Drug: PF-07934040 · Combination product: Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab | Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | 64 | 2024-06-27 | 2026-10-09 | in 50 d | 2026-07-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsNCT07318805Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT) | Phase 1 | Recruiting | Drug: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab | Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer | 260 | 2025-12-23 | 2029-04-14 | in 968 d | 2026-07-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsNCT06607185Number of Participants with Dose-limiting Toxicities (DLTs) | Phase 1 | Active, not recruiting | Drug: LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab | Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor | 750 | 2024-10-21 | Jan 2030 | ≤ 1,260 d | 2026-07-20 |
| EXEL | Exelixis | $13.2B | Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerNCT05425940Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in All Randomized Participants | Phase 3 | Active, not recruiting | Drug: XL092, Atezolizumab, Regorafenib | Colorectal Cancer | 901 | 2022-09-07 | 2026-06-16actual | — | 2026-07-17 |
| NTHI | Neonc Technologies, Inc. | $143M | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain | Phase 1/2 | Recruiting | Drug: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma | 134 | 2023-11-01 | 2027-02-28 | in 192 d | 2026-07-16 |
| BNTX | BioNTech SE | — | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal CancerNCT04486378Disease-free survival (DFS) | Phase 2 | Active, not recruiting | Drug: RO7198457 intravenous (IV) · Other: Observational group (no intervention) | Colorectal Cancer Stage II, Colorectal Cancer Stage III | 327 | 2021-03-08 | Nov 2026 | ≤ 102 d | 2026-07-15 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Drug: IDE-161, Pembrolizumab | Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC | 216 | 2023-04-18 | Oct 2026 | ≤ 72 d | 2026-07-13 |
| ELTX | Elicio Therapeutics | $82M | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid TumorsNCT05726864Phase 1: Evaluate the safety of ELI-002 7P | Phase 1/2 | Active, not recruiting | Drug: ELI-002 7P | Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S | 158 | 2023-04-14 | 2026-04-20actual | — | 2026-07-10 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | Drug: Zanidatamab | Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression | 200 | 2025-01-14 | 2026-12-31 | in 133 d | 2026-07-10 |
| AKTS | Aktis Oncology, Inc. | — | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsNCT07020117Part 1: Number of Patients with Dose-Limiting Toxicities | Phase 1 | Recruiting | Drug: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) | Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer | 150 | 2025-08-22 | Dec 2027 | ≤ 498 d | 2026-07-10 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of DiseaseNCT07023289Percentage of Participants with disease free survival (DFS) Event | Phase 2 | Recruiting | Drug: Telisotuzumab Adizutecan, Standard of Care | Colorectal Cancer | 140 | 2025-09-02 | Nov 2029 | ≤ 1,198 d | 2026-07-10 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsNCT07349537Number of patients with adverse events (AEs) | Phase 1 | Recruiting | Drug: RMC-5127, daraxonrasib, cetuximab | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC, NSCLC, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Solid Tumors | 574 | 2026-01-08 | Apr 2028 | ≤ 619 d | 2026-07-10 |
| LLY | Eli Lilly and Company | $1.15T | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsNCT02009449results2026-07-09Number of Participants With TEAEs and SAEs Observed During the Study of Pegilodecakin | Phase 1 | Completed | Drug: Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin | Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer | 353 | 2013-11-15 | 2019-02-19actual | — | 2026-07-09 |
| IMNM | Immunome, Inc. | $3.1B | A Phase 1 Study of IM-1617 in Participants With Advanced CancerNCT07578571Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of adverse events (AEs) and serious adverse events (SAEs) | Phase 1 | Recruiting | Drug: IM-1617 | Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer, Stomach Cancer, Cancer | 175 | 2026-05-21 | Jan 2029 | ≤ 895 d | 2026-07-09 |
| ONC | BeOne Medicines | $545.6B | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or AmplificationNCT06585488Phase 1a: Number of Participants Experiencing Adverse Events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape. | Drug: BGB-53038, Tislelizumab, Cetuximab | Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Cancer, Advanced Esophageal Adenocarcinoma | 47 | 2024-12-13 | 2026-04-23actual | — | 2026-07-08 |
| AZN | AstraZeneca | — | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursNCT06147037Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068 | Phase 1 | Active, not recruiting | Drug: FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068 | Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma | 13 | 2024-07-31 | 2026-12-31 | in 133 d | 2026-07-07 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of SGN-MesoC2 in Advanced Solid TumorsNCT06466187Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Drug: PF-08052666 | Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial | 19 | 2024-08-02 | 2026-05-27actual | — | 2026-07-07 |
| SNDX | Syndax Pharmaceuticals | $1.8B | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid TumorsNCT05731947results2026-07-06Phase 1a: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) | Phase 1/2 | Terminatedsponsor's stated reason: Study was terminated by sponsor after Phase 1b as pre-defined signals of efficacy were not met in the Phase 1b dose expansion cohort. | Drug: Revumenib, Chemotherapy | Colorectal Cancer, Solid Tumors | 41 | 2023-04-04 | 2025-06-30actual | — | 2026-07-06 |
| CATX | Perspective Therapeutics | $366M | Lead-212 PSV359 Therapy for Patients With Solid TumorsNCT06710756Determination of safety and tolerability of [203Pb]Pb-PSV359 | Phase 1/2 | Recruiting | Drug: [203Pb]Pb-PSV359, [212Pb]Pb-PSV359 | Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma | 112 | 2025-04-28 | 2028-01-31 | in 529 d | 2026-07-06 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsNCT05571839Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety concerns. | Drug: PF-08046049 | Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma | 41 | 2023-01-03 | 2026-06-01actual | — | 2026-07-01 |
| BNTX | BioNTech SE | — | A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal CancerNCT07079631Phase I - Part A: Occurrence of dose limiting toxicities (DLTs) during the DLT observation period | Phase 1/2 | Recruiting | Biological: BNT314 · Drug: Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab | Metastatic Colorectal Cancer | 482 | 2025-07-18 | Dec 2030 | ≤ 1,594 d | 2026-07-01 |
| 3402.T | Toray Industries, Inc | $12.6B | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsNCT03872947Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0 | Phase 1 | Active, not recruiting | Biological: TRK-950, TRK-950, TRK-950 · Drug: Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD | Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 138 | 2019-04-26 | Jun 2026 | — | 2026-06-23 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4170156 in Participants With Selected Advanced Solid TumorsNCT06400472Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156 | Phase 1 | Recruiting | Drug: LY4170156, bevacizumab, carboplatin, Itraconazole, pembrolizumab | Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms | 495 | 2024-05-20 | Feb 2027 | ≤ 192 d | 2026-06-18 |
| LLY | Eli Lilly and Company | $1.15T | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsNCT06586515Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Recruiting | Drug: LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil | Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer | 630 | 2024-09-12 | Mar 2029 | ≤ 954 d | 2026-06-18 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesNCT07503808Safety and tolerability of IDE034 in Part 1 dose escalation | Phase 1 | Recruiting | Drug: IDE034 | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer | 150 | 2026-02-24 | 2027-07-30 | in 344 d | 2026-06-18 |
| GEHC | GE Healthcare | $33.0B | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)NCT07219238Per-region sensitivity and Per-region specificity of GEH300079 (68Ga) PET/CT imaging to detect PC. | Phase 2/3 | Recruiting | Drug: GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Colorectal Cancer, Gastric Cancers, Ovarian Cancers, Pancreatic Ductal Adenocarcinoma | 175 | Oct 2026 | Jun 2029 | ≤ 1,045 d | 2026-06-17 |
| CRDF | Cardiff Oncology | $69M | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationNCT06106308Objective Response Rate (ORR) | Phase 2 | Active, not recruiting | Drug: Onvansertib, FOLFIRI, Bevacizumab, FOLFOX | Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation | 110 | 2024-02-27 | Nov 2026 | ≤ 102 d | 2026-06-16 |
| CNTX | Context Therapeutics Inc. | $49M | CT-95 in Advanced Cancers Associated With Mesothelin ExpressionNCT06756035Determine the MTD or RD of CT-95 [Safety and Tolerability] | Phase 1 | Recruiting | Drug: CT-95 | Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer | 70 | 2025-03-31 | Dec 2026 | ≤ 133 d | 2026-06-12 |
| AZN | AstraZeneca | — | First in Human Study of AZD9592 in Solid TumorsNCT05647122Incidence of Adverse Events (AEs) | Phase 1 | Active, not recruiting | Drug: AZD9592, Osimertinib, 5-Fluorouracil (5-FU), Leucovorin, Bevacizumab | Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms | 167 | 2022-12-21 | 2028-08-03 | in 714 d | 2026-06-11 |
| LYEL | Lyell Immunopharma, Inc. | $332M | LYL273 for Patients With Relapsed or Refractory mCRCNCT05319314Phase 1: Incidence of adverse events (AEs) defined as dose-limiting toxicities (DLTs) during 3+3 dose escalation study | Phase 1/2 | Recruiting | Drug: LYL273 | Colorectal Cancer | 155 | 2022-08-01 | Jun 2028 | ≤ 680 d | 2026-06-09 |
| IDYA | IDEAYA Biosciences | $3.7B | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsNCT03947385Dose-limiting Toxicity (DLT) | Phase 1/2 | Recruiting | Drug: IDE196, Binimetinib, Crizotinib | Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors | 336 | 2019-06-28 | 2027-01-29 | in 162 d | 2026-06-08 |
| KURA | Kura Oncology, Inc. | $1.1B | KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410Rate of dose-limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: Darlifarnib, Cabozantinib, Adagrasib | Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC) | 300 | 2023-10-18 | Jan 2027 | ≤ 164 d | 2026-06-08 |
| ISRG | Intuitive Surgical | $138.2B | da Vinci SP® Investigational Device Exemption Study in Colorectal ProceduresNCT04403022results2026-06-03Rate of Conversion | Not applicable | Active, not recruiting | Device: Robotic Assisted Surgery | Colorectal Cancer, Benign or Malignant Rectal or Colon Tumors | 60 | 2021-06-03 | 2023-09-30actual | — | 2026-06-03 |
| PFE | Pfizer | $155.3B | Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15NCT05546476results2025-04-29Part A: Change From Baseline in Body Weight at Week 12 | Phase 2 | Completed | Drug: ponsegromab, Placebo for ponsegromab | Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite, Fatigue, Cachexia | 187 | 2022-11-21 | 2024-03-13actual | — | 2026-06-03 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsNCT06040541Adverse events | Phase 1 | Recruiting | Drug: RMC-9805, RMC-6236 | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors | 604 | 2023-09-07 | 2026-12-31 | in 133 d | 2026-06-03 |
| PFE | Pfizer | $155.3B | An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.NCT07527832observationalIncidence rate of "haemorrhage" | — | Completed | Drug: Bevacizumab-Pfizer Biosimilar, Avastin | Colorectal Cancer | 1,000 | 2026-04-20 | 2026-05-27actual | — | 2026-06-03 |
| GH | Guardant Health, Inc. | $21.5B | Decision Counseling and Follow-up for Shield+ PatientsNCT07620535observationalCDE Decisional Conflict | — | Not yet recruiting | Behavioral: Decision Counseling Session | Colo-rectal Cancer | 350 | Jun 2026 | Dec 2027 | ≤ 498 d | 2026-06-02 |
| JANX | Janux Therapeutics | $1.0B | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesNCT05783622Incidence of Dose Limiting Toxicities (DLT) | Phase 1 | Active, not recruiting | Drug: JANX008 | Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer | 130 | 2023-04-19 | 2026-07-31 | — | 2026-06-01 |
| DCTH | Delcath Systems Inc. | $585M | Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant DiseaseNCT06607458hPFS | Phase 2 | Recruiting | Drug: Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone | Refractory Metastatic Colorectal Cancer | 90 | 2025-08-05 | Dec 2026 | ≤ 133 d | 2026-06-01 |
| LLY | Eli Lilly and Company | $1.15T | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)NCT04956640Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy | Phase 1/2 | Active, not recruiting | Drug: LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin | Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms | 540 | 2021-07-19 | Apr 2027 | ≤ 253 d | 2026-05-29 |
| ABBV | AbbVie | $457.5B | A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal CancerNCT06614192Percentage of Participants with Adverse Events (AE)s | Phase 3 | Active, not recruiting | Drug: Telisotuzumab Adizutecan | Metastatic Colorectal Cancer | 74 | 2024-11-08 | Aug 2027 | ≤ 376 d | 2026-05-28 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesNCT07223047Number of participants with adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986523, Gemcitabine, Nab-Paclitaxel, Cetuximab, Pembrolizumab | Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) | 252 | 2025-11-25 | 2028-10-13 | in 785 d | 2026-05-28 |
| AZN | AstraZeneca | — | A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)NCT00600496Safety and tolerability of twice daily oral doses of AZD6244 when administered in combination with standard doses of selected chemotherapies. | Phase 1 | Completed | Drug: AZD6244, Dacarbazine, Erlotinib, Docetaxel, Temsirolimus | Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer | 140 | 2007-12-14 | 2010-08-20actual | — | 2026-05-27 |
| INBX | Inhibrx Biosciences, Inc | $1.4B | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including SarcomasNCT03715933Frequency and severity of adverse events of INBRX-109 | Phase 1 | Recruiting | Drug: INBRX-109, Irinotecan, Temozolomide, carboplatin, pemetrexed, Leucovorin, Fluorouracil, Bevacizumab, Trifluridine + Tipiracil | Ewing Sarcoma, Colorectal Adenocarcinoma | 411 | 2018-10-08 | Dec 2028 | ≤ 864 d | 2026-05-22 |
| BNTX | BioNTech SE | — | Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant ChemotherapyNCT04813627observationalOccurrence of ctDNA positivity in the post-surgery/pre-AdCTx blood sample | — | Completed | Procedure: Regular blood sample collection for ctDNA assessment | Colorectal Cancer Stage II, Colorectal Cancer Stage III | 2,079 | 2021-07-02 | 2025-04-23actual | — | 2026-05-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.NCT06704724Part 1 & 2: Incidence of Adverse Events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns. | Drug: PF-07985045 · Combination product: Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, Sasanlimab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, PF-07284892 | Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | 30 | 2024-12-10 | 2026-05-12actual | — | 2026-05-22 |
| CYDY | CytoDyn, Inc. | $269M | The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)NCT06699836The efficacy of leronlimab in combination with trifluridine and tipiracil + bevacizumab in participants with relapsed, refractory, MSS, mCRC. | Phase 2 | Active, not recruiting | Drug: 350 mg leronlimab, 700 mg leronlimab | Metastatic Colorectal Cancer (mCRC) | 66 | 2025-06-16 | Jan 2028 | ≤ 529 d | 2026-05-18 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsNCT07094204Incidence of Dose Limiting Toxicities (DLTs) (Dose Escalation only) | Phase 1 | Recruiting | Drug: ASP5834, panitumumab | Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | 364 | 2025-07-25 | 2028-11-30 | in 833 d | 2026-05-18 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASNCT05379985Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs | Phase 1/2 | Recruiting | Drug: RMC-6236 | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors | 754 | 2022-05-31 | 2027-05-31 | in 284 d | 2026-05-15 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsNCT05462717Adverse events | Phase 1 | Active, not recruiting | Drug: RMC-6291 | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor | 222 | 2022-09-19 | 2027-03-31 | in 223 d | 2026-05-15 |
| AGEN | Agenus Inc. | $339M | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalNCT06751524expanded access | — | Available | Drug: Botensilimab, Balstililmab | Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC), Melanoma, Sarcoma, Ovarian Cancer, Prostate Cancer | — | — | — | — | 2026-05-15 |
| GH | Guardant Health, Inc. | $21.5B | Evaluation of the ctDNA LUNAR Test in an Average Patient Screening EpisodeNCT04136002observationalSensitivity of colorectal cancer detection | — | Active, not recruiting | — | Colorectal Cancer | 44,467 | 2019-10-08 | 2024-03-20actual | — | 2026-05-14 |
| ALXO | ALX Oncology Inc. | $288M | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsNCT07085091Phase 1a: Incidence of dose limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: ALX2004, ALX2004, ALX2004 | NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC) | 170 | 2025-08-18 | Jun 2027 | ≤ 314 d | 2026-05-12 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal CancerNCT06464692Dose-Limiting Toxicity (DLT) of Telisotuzumab Adizutecan in Stage 1 | Phase 1 | Active, not recruiting | Drug: Telisotuzumab Adizutecan | Colorectal Cancer | 31 | 2024-09-30 | Dec 2027 | ≤ 498 d | 2026-05-11 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsNCT05983133Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Drug: PF-08046052 | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma | 68 | 2023-11-14 | 2026-04-16actual | — | 2026-05-05 |
| MGNX | MacroGenics | $261M | A Study of MGC028 in Participants With Advanced Solid TumorsNCT06723236Number and Types of Adverse Events (AEs) in Participants Receiving MGC028 | Phase 1 | Recruiting | Biological: MGC028 | Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma | 124 | 2025-02-13 | Nov 2026 | ≤ 102 d | 2026-04-27 |
| VSTM | Verastem, Inc. | $673M | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsNCT07020221Part A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375 | Phase 1/2 | Recruiting | Drug: VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine, Gemcitabine + Nab-paclitaxel | Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS | 295 | 2025-06-24 | Dec 2028 | ≤ 864 d | 2026-04-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)NCT03157128results2026-04-16Phase 1: Maximum Tolerated Dose (MTD) | Phase 1/2 | Active, not recruiting | Drug: LOXO-292 | Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor | 857 | 2017-05-02 | 2025-02-14actual | — | 2026-04-16 |
| AZN | AstraZeneca | — | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsNCT06973161observationalOverall Survival | — | Completed | — | Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, Other Tumors | 140 | 2025-06-10 | 2026-03-17actual | — | 2026-04-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Colorectal Cancer is matched — 28 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Colorectal Cancer
- Metastatic Colorectal Cancer
- Colorectal Neoplasms
- Colon Cancer
- Colorectal Carcinoma
- Colorectal Cancer (CRC)
- Rectal Cancer
- Colorectal Cancer Metastatic
- Rectal Neoplasms
- CRC
- Colo-rectal Cancer
- Colorectal Neoplasm
- Advanced Colorectal Cancer
- CRC (Colorectal Cancer)
- Colon Cancer Liver Metastasis
- Colorectal Adenocarcinoma
- Metastatic Colorectal Cancer (mCRC)
- Microsatellite Stable Colorectal Cancer
- Unresectable Metastatic Colorectal Cancer
- Advanced Colorectal Cancer (Part 1)
- Colorectal Cancer Stage II
- Colorectal Cancer Stage III
- Colorectal Carcinoma (CRC)
- Colorectal Tumor
- Metastatic Colorectal Carcinoma
- Mismatch Repair Deficient Colorectal Cancer
- Rectal Adenocarcinoma
- Refractory Metastatic Colorectal Cancer
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Colorectal Cancer” (a text search, wider than this page)